These two immunophenotypes (HLA-I+/PD-L1+ versus HLA-I–/PD-L1+) could potentially be associated with the response versus resistance to immunotherapy with tumor HLA-I expression being a pivotal factor and a driving force of tumor rejection in response to immunotherapy. The gene discussed is CD274; the disease is neoplasm.